What is the recommended diagnostic workup and initial treatment for a patient with suspected interstitial lung disease?

Diagnostic Workup for Suspected Interstitial Lung Disease

For patients with suspected ILD, obtain high-resolution CT (HRCT) of the chest as the primary diagnostic test, perform pulmonary function tests (PFTs) including spirometry and DLCO, and take a detailed history of medication use, environmental/occupational exposures, and serological testing to exclude connective tissue disease 1.

Initial Diagnostic Algorithm

Step 1: Clinical Assessment

Obtain specific details about:

• Dyspnea on exertion (present in most ILD cases) and dry cough (present in ~30% of cases) 2
• Medication history (drug-induced ILD)
• Environmental exposures at home, work, and other frequent locations (hypersensitivity pneumonitis, occupational ILD)
• Symptoms suggesting connective tissue disease (joint pain, rash, Raynaud's phenomenon, muscle weakness)
• Smoking history (affects differential diagnosis and prognosis)
• Family history of pulmonary fibrosis (genetic predisposition in ~30% of cases) 1

Step 2: High-Resolution CT Technique

HRCT is approximately 91% sensitive and 71% specific for diagnosing ILD subtypes 2. Technical requirements include 1:

• Volumetric acquisition with thinnest collimation, shortest rotation time, highest pitch
• First acquisition: supine position at sustained end-inspiration
• Second acquisition: supine position at sustained end-expiration over entire thorax
• Reduced-dose CT protocols per current recommendations

Key HRCT patterns to identify:

• UIP pattern: Honeycombing, subpleural/basal predominant reticulation with traction bronchiectasis
• Probable UIP pattern: Requires further evaluation with possible biopsy 1
• Fibrotic patterns: Fibrotic NSIP, fibrotic hypersensitivity pneumonitis
• Ground-glass opacities: Suggest inflammatory/cellular disease potentially more responsive to treatment

Step 3: Pulmonary Function Testing

Perform complete PFTs including 2:

• Forced vital capacity (FVC): Baseline and for monitoring (5% decline over 12 months associated with ~2-fold mortality increase)
• DLCO: Typically reduced in ILD
• Total lung capacity (TLC): Restrictive pattern expected
• Repeat every 3-6 months initially, especially in first 1-2 years 3

Step 4: Laboratory Testing

Mandatory serological testing 1:

• Antinuclear antibody (ANA)
• Rheumatoid factor (RF)
• Anti-CCP antibodies
• Anti-Scl-70 (systemic sclerosis)
• Anti-Jo-1 and other myositis-specific antibodies
• Anti-SSA/SSB (Sjögren's)

Do NOT routinely measure 1:

• Serum MMP-7, SPD, CCL-18, or KL-6 for distinguishing IPF from other ILDs (strong recommendation against)

Step 5: Bronchoscopy with BAL (Selective Use)

Perform BAL cellular analysis when 1, 4:

• HRCT shows probable UIP or indeterminate pattern (NOT confident UIP pattern)
• Need to exclude alternative diagnoses (infection, malignancy, eosinophilic pneumonia)
• Target BAL site based on HRCT findings rather than traditional right middle lobe/lingula 4

BAL findings that narrow differential 4:

• Lymphocytosis (>25%): Suggests hypersensitivity pneumonitis, NSIP, drug-induced ILD, or sarcoidosis
• Neutrophilia/eosinophilia: Suggests fibrosing process (IPF, CTD-ILD, asbestosis)
• Normal differential: Does NOT exclude ILD

Do NOT perform BAL 1:

• When HRCT shows confident UIP pattern (conditional recommendation against)
• BAL has no established prognostic value or ability to predict treatment response 4

Step 6: Lung Biopsy Decision-Making

For HRCT pattern of UIP: Strongly recommend NOT performing surgical lung biopsy 1

For HRCT pattern of probable UIP: Conditionally suggest performing surgical lung biopsy 1

Surgical lung biopsy (video-assisted thoracoscopic preferred) when 1:

• Atypical clinical, radiological, or physiological features
• HRCT indeterminate or inconsistent with UIP
• Patient age <70 years, acceptable surgical risk
• Diagnosis would significantly alter management

Strongly recommend against transbronchial lung biopsy and cryobiopsy for IPF diagnosis 1

Step 7: Multidisciplinary Discussion

Conditionally recommend multidisciplinary discussion involving pulmonologists, radiologists, and pathologists for diagnostic decision-making, particularly for complex or atypical cases 1.

---

Initial Treatment Approach

For Idiopathic Pulmonary Fibrosis (IPF)

Initiate antifibrotic therapy with nintedanib or pirfenidone, which slow annual FVC decline by 44-57% 2. These are the only FDA-approved therapies for IPF.

For Connective Tissue Disease-Associated ILD

First-line treatment hierarchy 5:

Systemic Sclerosis-ILD:

• Mycophenolate (preferred first-line)
• Tocilizumab, nintedanib, rituximab, cyclophosphamide (additional options)
• Strongly recommend AGAINST glucocorticoids (risk of scleroderma renal crisis) 5

Rheumatoid Arthritis-ILD:

• Mycophenolate (preferred first-line)
• Azathioprine, rituximab, cyclophosphamide (additional options)
• Conditionally recommend glucocorticoids as first-line (not for SSc-ILD) 5

Inflammatory Myopathy-ILD:

• Mycophenolate (preferred first-line)
• JAK inhibitors, calcineurin inhibitors (additional options for refractory disease)
• Conditionally recommend glucocorticoids 5

Sjögren's Disease-ILD:

• Mycophenolate (preferred first-line)
• Azathioprine, rituximab, cyclophosphamide
• Moderate-dose oral corticosteroids for symptomatic disease (≤60 mg prednisone daily with slow taper) 3

For Rapidly Progressive ILD

Initiate pulse intravenous methylprednisolone plus combination therapy 5:

• Triple therapy for MDA-5 positive myositis (glucocorticoids + 2 immunosuppressants)
• Double therapy for other rapidly progressive cases
• First-line agents: rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors, JAK inhibitors 5

Supportive Care (All ILD Types)

• Supplemental oxygen for desaturation <88% on 6-minute walk test 2
• Pulmonary rehabilitation: Improves 6-minute walk distance and quality of life 2
• Smoking cessation (mandatory)
• Consider gastroesophageal reflux management with proton pump inhibitors 5
• Pneumocystis jirovecii prophylaxis when using immunosuppression

Monitoring for Disease Progression

Progressive pulmonary fibrosis criteria (within 24 months) 5:

• FVC decline ≥10% predicted, OR
• FVC decline 5-10% predicted PLUS worsening respiratory symptoms or increased fibrosis on HRCT, OR
• Worsening respiratory symptoms AND increased fibrosis on HRCT

For progressive disease despite first-line treatment:

• Add nintedanib for SSc-ILD, RA-ILD, or progressive fibrosing ILD 5
• Switch or add alternative immunosuppressants based on specific CTD subtype
• Consider early lung transplant referral for refractory cases 5

---

Critical Pitfalls to Avoid

1. Do not delay HRCT in patients with unexplained dyspnea and crackles on examination
2. Do not use transbronchial biopsy or cryobiopsy to diagnose IPF 1
3. Do not use glucocorticoids in systemic sclerosis-ILD (strong recommendation against due to renal crisis risk) 5
4. Do not perform surgical lung biopsy when HRCT shows confident UIP pattern 1
5. Do not delay antifibrotic therapy in confirmed IPF—early treatment preserves lung function 2
6. Do not use serum biomarkers (MMP-7, SPD, CCL-18, KL-6) for routine diagnosis 1